Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829439 · ClinicalTrials.gov registry record · Phase 1
Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome
A Phase 1 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00829439 is a Phase 1 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 16 participants.
The verdict
NCT00829439, a Phase 1 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in children with Angelman syndrome. Data from this study will be used to design a phase II trial to determine the efficacy of levodopa in treating children with Angelman syndrome.
Interventions
- DRUG Levodopa/Carbidopa (4:1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829439
The ClinicalTrials.gov registry entry for NCT00829439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levodopa/Carbidopa (4:1) is the first listed.
NCT00829439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829439 about?
NCT00829439 is a clinical study titled "Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome". This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesized that levodopa may lead to an improvement in the neurodevelopment and abnormal movements (e.g. tremors) in ch...
What is the current status of trial NCT00829439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00829439?
The interventions under investigation include: Levodopa/Carbidopa (4:1) (DRUG).
Who is sponsoring clinical trial NCT00829439?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.